Topics:

Practice & Policy

USPSTF Recommends Low-Dose CT Screening for Heavy Smokers

The USPSTF published its final recommendation on screening for lung cancer on December 31, concluding that all people between the ages of 55 and 80 years who are at high risk for lung cancer should undergo low-dose CT screening.

Practice & Policy

Ahead of the World Tobacco Congress, Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 1 examines the early evidence linking smoking with cancer.

The US Food and Drug Administration has approved filgrastim-sndz (Zarxio), a biosimilar of filgrastim (Neupogen), and the first such agent to be approved in the United States.

A new study suggests that cancer patients do not often request unnecessary and sometimes costly tests or treatments.

CMS has launched a new multi-payer cancer payment model that reimburses oncologists for episodes of care surrounding chemotherapy treatment, part of a larger effort by the agency to reward physicians based on quality rather than quantity of care.

I do not want politicians passing laws to tell us how to practice. The legislative process cannot keep pace with changes in medicine.

An FDA advisory panel unanimously endorsed EP2006, a biosimilar of filgrastim, a biologic used to treat neutropenia caused by chemotherapy treatment.

Experts from ASCO and AACR have penned a statement for policymakers on the potential negative effects of e-cigarettes and other nicotine-deliveries electronics.

Pages

Subscribe to Practice & Policy on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.